1 Mineral supplements, hydrochlorothiazide and potassium-sparing agents, beta-blockers, angiotensin 2 r

2 or antagonists have been used effectively as potassium-sparing and renal-function-protective diuretic

3 While blockade of ASIC1 through amiloride, a potassium sparing diuretic that is currently licensed fo

4                           Derivatives of the potassium-sparing diuretic amiloride are preferentially

5                                     Only non-potassium-sparing diuretic use was independently associa

6  Conclusions-In SOLVD, baseline use of a non-potassium-sparing diuretic was associated with an increa

7  arrhythmic death, whereas baseline use of a potassium-sparing diuretic was not.

8                                     Use of a potassium-sparing diuretic, alone or in combination with

9 sessed whether addition or substitution of a potassium-sparing diuretic, amiloride, to treatment with

10 diuretic, alone or in combination with a non-potassium-sparing diuretic, was not independently associ

11           We sought to determine whether non-potassium-sparing diuretics (PSDs) in the absence of a P

12 th in hypertensive patients treated with non-potassium-sparing diuretics is reported.

13 losing tubulopathy, are usually treated with potassium-sparing diuretics or nonsteroidal anti-inflamm